| HS Code | 319100 |
| Productname | Foot and Mouth Disease (Type A) Vaccine, Inactivated (Strain AF/72) Veterinary Grade API |
| Producttype | Inactivated viral antigen bulk API for veterinary vaccine manufacture |
| Diseasetarget | Foot and Mouth Disease (FMD), serotype A |
| Virusstrain | AF/72 |
| Inactivationstatus | Chemically inactivated, non-infectious virus |
| Targetspecies | Cattle, buffalo, sheep, goats, pigs and susceptible cloven-hoofed animals |
| Administrationroute | Subcutaneous or intramuscular injection after formulation |
| Adjuvantrequirement | Requires adjuvants such as aluminum hydroxide, oil emulsion or saponin |
| Physicalform | Liquid concentrate or suspension |
| Shelflife | Typically 12 to 24 months when stored under proper cold-chain conditions |
As an accredited Foot and Mouth Disease(Type A)Vaccine,Inactivated(Strain AF/72) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Each pack contains 100 mL of sterile Foot and Mouth Disease (Type A) Vaccine, Inactivated (AF/72), in sealed multi-dose glass vials. |
| Container Loading (20′ FCL) | 20′ FCL for Foot and Mouth Disease (Type A) inactivated vaccine (strain AF/72) veterinary API. Maintain cold chain, secure packaging, and complete documentation. |
| Shipping | Ship this veterinary vaccine API under strict cold chain at 2–8°C. Use validated insulated packaging with ice packs or dry ice, temperature indicators, and expedited courier service. Protect from light and freezing. Label as Biological Substance Category B (UN 3373). Maintain continuous temperature monitoring throughout transit to preserve potency. |
| Storage | Store at 2–8°C in a dark, dry, well-ventilated area. Do not freeze or expose to excessive heat or direct sunlight. Keep container tightly sealed, away from incompatible substances. Use aseptic handling during formulation. Protect from moisture for powder/granule forms. Follow manufacturer expiry and handling guidelines for veterinary use. |
| Shelf Life | Shelf life: 24 months from manufacture when stored at 2–8°C, protected from light, in unopened containers. |
In antigen bank and working seed lot operations, the inactivated AF/72 antigen concentrate is handled as a high-value biological API rather than a conventional chemical raw material. The concentrate is stored in vapour-phase liquid nitrogen below -135°C or in mechanical freezers at -65°C to -80°C for long-term retention, with short-term processing at 2–8°C. Viral inactivation with binary ethyleneimine (BEI) generated from 2-bromoethylamine hydrobromide at 1–3 mM and 26°C for 24 h is followed by neutralization with sodium thiosulfate; inactivation charts must show linear decline to below the detectable infectious-virus threshold before the material is released from containment. Clarified harvest is concentrated by tangential flow filtration or polyethylene glycol precipitation, then the 146S antigen peak is quantified by sucrose density gradient ultracentrifugation with UV absorbance integration. The release specification for the antigen concentrate includes 146S concentration, total protein, residual BEI, identity by strain-specific neutralization or antigen ELISA against AF/72 reference serum, and sterility according to Ph. Eur. 2.6.1. During any pH adjustment, excursion below approximately pH 6.5 is avoided because 146S particles dissociate irreversibly into 12S pentamers; diafiltration buffers are therefore held at pH 7.2–7.8 and chilled to 2–8°C. Transfer lines use positive-displacement pumps and low-shear impellers, and hold times in jacketed stainless steel vessels before final formulation are kept to the shortest validated interval to limit capsid degradation.
Aqueous FMD vaccines using AF/72 antigen are compounded at pH 7.2–7.8 because the 146S particle is acid-labile; the aluminium hydroxide gel is pre-conditioned with buffered saline before antigen addition. A representative batch calculation illustrates the dilution ratio: if the AF/72 concentrate contains 8–12 µg 146S/mL and the monovalent target is 1.0–2.0 µg 146S per 2 mL dose, then 0.10–0.25 mL of antigen concentrate is added per dose before the adjuvant phase is introduced. The saponin co-adjuvant is added separately after aluminium hydroxide adsorption, because simultaneous addition can destabilize the gel matrix and produce variable antigen binding. Adsorption is performed at 2–8°C with low-shear agitation at 50–150 rpm for 30–60 min; excessive shear can strip bound antigen or create fine gel aggregates that fail visual inspection. Each aluminium hydroxide lot must be pre-qualified by an adsorption isotherm against AF/72 antigen, because the surface charge and phosphate content of the gel vary between suppliers and can shift the unadsorbed antigen fraction. The final aqueous vaccine is a suspension, not a true solution; settling may occur, and redispersal by gentle shaking is specified on the label. Potency release follows WOAH Terrestrial Manual Chapter 3.1.8; the accepted minimum is 3 PD50 per cattle dose, while 6 PD50 per dose is commonly applied for pigs. Published data for this specific AF/72 aqueous configuration is limited, so the exact 146S mass required to reach the PD50 target must be confirmed by in vivo titration in the target species.
For cattle and pig presentations, AF/72 antigen is formulated in water-in-oil or water-in-oil-in-water emulsions using mineral oil-based adjuvants. The aqueous antigen phase is mixed with the oil phase at a 50:50 mass ratio in a rotor-stator homogenizer with chilled recirculation; high-shear dispersion continues until the droplet size D50 reaches 1.0–3.0 µm as determined by laser diffraction according to ISO 13320:2020. Emulsion temperature is maintained below 25°C through jacketed vessel cooling, because local thermal spikes above 30°C accelerate 146S capsid degradation. Final W/O emulsion viscosity typically falls between 20 mPa·s and 80 mPa·s at 20°C using a rotational viscometer with spindle geometry defined in the batch record; values above 100 mPa·s require a larger needle diameter or brief warming to 20–25°C immediately before administration. Release tests include emulsion stability after 24 h at 4°C and 37°C, droplet size distribution, aqueous phase pH after emulsion breaking, and final container sterility. Sterile filtration of the final emulsion is generally not feasible due to viscosity and droplet retention; therefore, aseptic compounding of sterile raw materials is mandatory. The injectable dose volume is commonly 2 mL for cattle and 1–2 mL for pigs, but the AF/72 146S load is set by the potency assay rather than by mass alone. Shear rate, mixing time, and oil phase temperature are critical process parameters because an under-dispersed emulsion can coalesce during storage, while an over-dispersed emulsion can raise viscosity beyond injectability limits.
Multivalent FMD vaccine production requires AF/72 to be treated as one calibrated antigen among several type A and O strains; the blending order and strain-specific 146S input affect final potency. Antigen concentrates are thawed individually at 4°C, and each strain is dosed by its 146S content after monovalent potency titration. Antigenic matching against circulating field strains is determined by two-dimensional virus neutralization or ELISA; an r1 value below 0.3 indicates poor antigenic fit and cannot be compensated by raising total 146S mass. In a quadrivalent vaccine, the AF/72 component is added as a calculated volume of monovalent concentrate to a chilled buffer phase, then pumped through an inline static mixer at a flow rate validated to give a coefficient of variation of antigen distribution below 5% across the fill cycle. For a concentrate containing 8–12 µg 146S/mL and a target contribution of 1.0–2.0 µg 146S per 2 mL dose, the addition volume is 0.10–0.25 mL per dose before adjuvant mixing. pH adjustment of the pooled antigen solution is performed before adjuvant addition with dilute acetic acid or sodium hydroxide at 4°C under continuous pH monitoring, and the solution is not held at room temperature. AF/72 should be applied only where prevailing field strain r1 is 0.3 or higher unless emergency regulatory authorization is granted based on national FMD control policy.
Final filling of AF/72 solution-based and emulsion-based vaccines places stricter thermal limits on the API than standard sterile injectables. Terminal steam sterilization or gamma irradiation is not applicable to inactivated viral antigen; therefore, filling relies on pre-sterilized components and aseptic lines. Filling needles and tubing are chilled or insulated because the antigen bulk passes through pumps and can absorb heat from mechanical friction. In multi-hour fill campaigns, in-process hold vessels are maintained at 2–8°C and recirculated only if the recirculation loop is low-shear and validated not to increase aggregate particle count. For aqueous solution presentations without adjuvant, filling is followed by visual inspection for subvisible particles and pH confirmation; for W/O emulsions, viscosity and droplet size are repeated from filled container samples because filling can change the shear history of the product. The fill volume tolerance is typically ±0.1 mL for a 2 mL dose, but this may be tightened by national regulatory requirements. Container-closure integrity is verified by dye ingress or vacuum decay after capping, and the finished product is held at 2–8°C until release to the cold chain. No terminal heat step can be used to compensate for bioburden in bulk AF/72 solution because even short exposure to 37°C reduces 146S integrity.
Commercial tablets, capsules, and premix powders are not established presentations for inactivated FMD vaccines in the EU, US, or WOAH-listed countries, because the AF/72 146S particle dissociates at gastric pH. Investigational dry-powder formulations therefore require enteric protection or acid-neutralizing buffer systems matched to the gastric pH-time profile of the target species. Lyophilization of AF/72 antigen would require cryoprotectants such as trehalose or sucrose at mass ratios of 1:1 to 5:1 relative to total protein, with primary drying below the collapse temperature and secondary drying to residual moisture below 2%. Granule or premix intermediates are prepared by fluid-bed spray granulation onto lactose or mannitol carriers, but every heated unit operation must keep product temperature below 30°C to avoid 146S degradation. Published formulation data for this specific AF/72 dry-powder configuration is limited; no potency value for oral AF/72 powder can be extrapolated from injectable data. If powder, granule, or premix dosage forms are evaluated, only methods validated for mucosal IgA induction can support a dosing ratio, and acid-protective excipients must be selected according to pH-time profiles in the rumen or stomach of the target species.
Competitive Foot and Mouth Disease(Type A)Vaccine,Inactivated(Strain AF/72) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The subject product is Foot and Mouth Disease (Type A) Vaccine, Inactivated (Strain AF/72) Veterinary Grade API. The designation identifies an inactivated foot-and-mouth disease virus type A antigen concentrate derived from the AF/72 seed lineage, not a finished veterinary vaccine. The strain designation AF/72 serves as the product-defining biological model identifier. The phrase “for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions” defines downstream processing routes into which the active substance may be incorporated under validated manufacturing conditions; it does not by itself authorise every route, species, or disease indication. Release and formulation of the API are controlled according to the registration dossier, applicable veterinary biological standards including OIE Terrestrial Manual Chapter 3.1.8, and current good manufacturing practice for biological active substances such as ICH Q7 where adopted. The principal quality target is preservation of the intact 146S virus particle. Degradation to 75S or 12S components reduces neutralising antibody induction in target livestock. The material is therefore standardised by 146S mass per dose rather than by total viral protein alone. The inactivated state is demonstrated by absence of residual infectivity in susceptible cell culture after amplification, not solely by the chemical treatment record. The product is intended for industrial formulation and is not a direct-use stock solution.
Inactivation of FMDV type A AF/72 antigen is a critical process step. If binary ethyleneimine is used, 2-bromoethylamine hydrobromide is cyclised under alkaline conditions before virus exposure. The reaction is maintained at a defined temperature and time, and the kinetic curve should demonstrate linear first-order inactivation with a safety margin beyond the last positive sample. Residual binary ethyleneimine is neutralised with sodium thiosulfate. Lot release requires amplification in susceptible BHK-21 cells or equivalent; absence of cytopathic effect in a single passage is not sufficient because residual live virus may be present below the direct-assay detection limit. Inactivation parameters are process-specific, and published values for the AF/72 strain at production scale are limited unless disclosed in the manufacturer’s dossier.
Whole-culture inactivated FMDV preparations retain residual host-cell debris, serum protein, nucleic acid, and inactivating agent by-products. A purified AF/72 veterinary-grade API is normally clarified by depth filtration, concentrated by tangential-flow ultrafiltration, and polished by polyethylene glycol precipitation or chromatographic purification. These unit operations reduce endotoxin and host-cell impurities while preserving the 146S capsid. Purification does not expand the antigenic match to outbreak strains. Identity of AF/72 is confirmed by VP1 sequence analysis or antigenic typing with monospecific antisera. Differentiation from other type A lineages requires vaccine matching, commonly by two-dimensional virus neutralization or liquid-phase blocking ELISA; published comparative serological data for AF/72 against contemporary isolates is limited. The API differs from whole-culture antigen in that final antigen mass can be standardised by 146S content rather than by wet-weight or volume, which reduces potency variability but introduces purification recovery losses.
| Characteristic | Purified inactivated AF/72 API | Whole-culture inactivated FMDV antigen | Recombinant capsid or subunit antigen |
|---|---|---|---|
| Main antigenic moiety | 146S intact virus particle | Intact and degraded virus plus cell debris | Virus-like particle or subunit |
| Purification burden | High; ultrafiltration or gradient polishing | Low | Process-dependent |
| Endotoxin and host-cell impurity load | Reduced | Higher | Reduced |
| Potency basis | 146S mass per dose | Volume or inactivated antigen mass | Protein mass or particle count |
| Formulation adaptability | Injectable solution/emulsion; solid forms require lyophilization | Injectable emulsion primarily | Injectable or experimental mucosal |
| Published AF/72-specific comparative efficacy | Limited | Limited | Limited |
Among type A strains, AF/72 is not defined as a universal replacement for A/Argentina/2001, A24 Cruzeiro, or A Iran 05 lineages. Cross-protection varies according to capsid sequence, antigenic site mutations, and vaccine matching results. The manufacturer’s registration file should include homologous potency and expected heterologous relationship; no heterologous claim should be made without challenge or validated serological correlation.
Release testing for an inactivated FMDV type A API includes identity, sterility, bacterial endotoxins, residual live virus absence, residual inactivation agent, target antigen mass, and stability. Identity is confirmed by antigenic typing or VP1 sequence analysis. Sterility testing follows compendial membrane filtration where the matrix allows; for viscous or bacteriostatic intermediates, direct inoculation may be required. Bacterial endotoxins are controlled according to the intended final dose, with limits expressed per dose or per millilitre. Absence of residual live virus is demonstrated by at least two blind passages in susceptible BHK-21 or primary bovine thyroid cell culture; a single negative passage is insufficient for batch release. Residual binary ethyleneimine, if used, is controlled to a defined maximum. The potency-indicating parameter is usually 146S particle mass per millilitre, quantified after sucrose density gradient ultracentrifugation; 75S and 12S degradation components should remain below the acceptance limit established by the registration dossier.
| Attribute | Method example | Control objective |
|---|---|---|
| Identity | VP1 sequence or antigenic typing | Confirm AF/72 lineage |
| Sterility | Ph. Eur. 2.6.1 membrane filtration | Absence of viable bacteria and fungi |
| Bacterial endotoxin | Ph. Eur. 2.6.14 LAL | Vehicle-dependent limit |
| Residual infectivity | BHK-21 passage or immunofluorescence | No live virus |
| Residual inactivant | BEI titration or spectrophotometry | Below registered limit |
| Antigen integrity | Sucrose gradient or ELISA | Maintain 146S yield |
Production-scale processing bottlenecks occur principally during clarification and ultrafiltration. BHK-21 suspension harvests vary in host-cell DNA and protein content, which changes membrane flux and can shift the 146S recovery profile. Low-shear rotary lobe pumps and cooled housings are preferred because high-speed centrifugal pumps can fragment the viral capsid. Batch-to-batch variance in upstream titre is controlled through in-process 146S measurement before final standardisation. If the API is lyophilized, the freeze-dryer shelf temperature ramp and chamber pressure must be mapped to product temperature rather than shelf setpoint alone; collapse of the amorphous cake increases residual moisture and accelerates antigen loss. The API is typically stored frozen below −60°C or lyophilized at 2–8°C after stabilisation. Frozen liquid concentrates require controlled thawing; repeated freeze-thaw cycles reduce 146S recovery. Shipping containers are validated with temperature loggers and moisture-barrier closures.
Finished injections and solutions prepared from AF/72 API impose the most rigorous compatibility requirements. The antigen is diluted into adjuvanted or buffered vehicles under low-shear mixing; high shear fragments the 146S particle into 12S subunits. In water-in-oil and double-oil emulsions, the antigen is incorporated into the aqueous phase before emulsification with a rotor-stator device or membrane emulsifier. Droplet size is measured by laser diffraction; phase separation and viscosity are monitored with a rotational rheometer. Emulsion droplet size from 1 to 10 μm is commonly cited for water-in-oil veterinary vaccine emulsions, but the acceptable distribution for AF/72-containing formulations must be established in formulation development. Aqueous solutions require preservative compatibility testing because phenolic preservatives at elevated concentration denature the capsid. Powders, granules, and premix generally begin with lyophilized antigen blended with non-reducing carriers; residual moisture by Karl Fischer and glass transition temperature are release indicators. Injection-grade solutions and lyophilized powders for reconstitution are the most established presentations for inactivated FMDV antigen. Published data for oral solid presentations of this specific strain is limited.
Finished emulsions are tested for droplet size, viscosity, conductivity, phase separation, and syringeability through defined needle gauges. Syringeability and injection-site reactivity are formulation-specific; the API itself does not determine the final tissue response. If the API is supplied as a frozen liquid, thawing must be controlled in a water bath below 37°C or in a cold room. In-process bioburden is monitored before sterile filtration. Sterile filtration of a 146S-containing liquid requires filter selection with adequate pore size and low protein binding because adsorption losses can be significant if filter compatibility is not validated.
Tablets and capsules are non-standard presentations for FMDV immunogens because the licensed immune route for foot-and-mouth disease vaccines is normally parenteral. If a solid oral or transmucosal investigation is conducted, the dried AF/72 intermediate must be protected from compression heat, moisture, and incompatible excipients. Direct compression with low-moisture non-reducing fillers may be feasible; wet granulation with high-shear mixers exposes the antigen to aqueous conditions that favour aggregation and capsid loss. Dry granulation by slugging or roller compaction requires evaluation of shear and localised temperature. Coating with organic solvents or high inlet temperatures can damage the capsid; aqueous film coating is not appropriate unless the core is moisture-protected. Release tests include antigen recovery after dissolution in a validated buffer, dissolution, hardness, disintegration, and moisture. The oral route is expected to expose unprotected antigen to gastric or ruminal degradation; published data for this specific configuration is limited, so injectable efficacy data cannot be extrapolated to oral or transmucosal claims.
Primary packaging components for the API and finished product should be qualified for extractables and leachables. Elastomer closures may release accelerators or antioxidants that denature or aggregate the FMDV capsid. When the API is stored frozen, container integrity at −60°C is a process parameter. For lyophilized material, moisture-barrier containers and desiccant are used; headspace moisture is tested after storage. The selection of primary packaging is part of the stability protocol, not a secondary consideration.
Among other inactivated FMDV type A products, AF/72 identity is seed-specific; differences are defined by seed lot history, upstream cell substrate, inactivation kinetic parameters, purification scheme, and standardisation basis. The API differs from finished oil-adjuvanted vaccines because the adjuvant and preservative system are absent; from live attenuated vaccines because no replication-competent virus remains; from diagnostic-grade antigen because release is oriented to immunogenicity rather than serological detection; and from subunit or recombinant virus-like particle antigens because the intact inactivated virion retains the 146S conformational epitope array. Selection between AF/72 and another type A antigen must therefore be based on vaccine matching data, manufacturing compatibility, and the approved species-disease indication rather than on total protein concentration alone.
